

HAEMSTAR: HAEMATOLOGY SPECIALTY TRAINING AUDIT AND RESEARCH

England & Wales · Charity number 1199224

Details

Other names HAEMSTAR

Status Registered

Legal form Other

Registered 2022-06-09

Register [View on the Charity Commission register](#)

Contact

Address Office 129
Institute of Biomedical Research
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Phone 01214158678

Email haemstarnetwork@gmail.com

Website www.haemstar.org

Activities

Objects: THE OBJECT OF THE CHARITY IS:(1) TO PROTECT AND PRESERVE THE HEALTH OF PATIENTS SUFFERING FROM HAEMATOLOGICAL CONDITIONS BY:(A) THE PROMOTION OF CLINICAL RESEARCH INTO NON-MALIGNANT HAEMATOLOGY IN THE UNITED KINGDOM, THE CAUSES, PREVENTION AND TREATMENT OF HAEMATOLOGICAL CONDITIONS ON TERMS THAT THE RESULTS OF SUCH RESEARCH WILL BE PUBLISHED.(B) THE ADVANCEMENT OF EDUCATION AND TRAINING OF JUNIOR DOCTORS AND HAEMATOLOGISTS TO GIVE THEM THE SKILLS TO BECOME THE CHIEF AND PRINCIPAL INVESTIGATORS OF THE FUTURE.

Activities: We promote clinical research in Classical Haematology. We do this by: increasing participants recruitment to classical haematology clinical trials; transitioning local audits to large, national ones; developing our own studies; increasing exposure of haematology registrars to the NHS research environment.

Classification

- **How:** Provides Other Finance, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Arts/culture/heritage/science

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-05-31	£92,401	£47,130	-	-
2024-05-31	£54,928	£39,541	-	-
2023-05-31	£52,800	£5,022	-	-

Trustees

Name	Role	Appointed
Dr Phillip Lindsay Ross Nicolson	Chair	2021-03-31
Dr Andrew James Doyle		2021-03-31
Dr Emily Antonia Millen		2021-03-31
Dr Richard John Buka		2021-03-31
Dr Tom Paul Bull		2021-03-31

Accounts



CHARITY COMMISSION
FOR ENGLAND AND WALES

Trustees' Annual Report for the period

From 1/6/2024 Period start date To 31/5/2025 Period end date

Charity name: HaemSTAR: Haematology Specialist Training, Audit and Research

Charity registration number: 1199224

Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To protect and preserve the health of patients suffering from haematological conditions by: - the promotion of clinical research into Non-Malignant Haematology in the United Kingdom, the causes, prevention and treatment of haematological conditions on terms that the results of such research will be published. - the advancement of education and training of junior doctors and haematologists to give them the skills to become the chief and principal investigators of the future.'
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	During 1/6/24 to 31/5/25 we conceived, developed, ran, supported and/or wrote up nine projects. All of these projects further our charitable objects because - they all require project management (which is used to train junior doctors and haematologists in how to be researchers and principal investigators) and - they ultimately result in the publication of research findings that benefit patients. Projects take several years to complete from the time of inception. Activity completed from 1/6/24 to 31/5/25 is highlighted in red: AudHIT – Heparin- Induced Thrombocytopaenia audit Type of study: retrospective, multi-centred national audit Topic: National Audit evaluating diagnosis and management of HIT against BSH guidelines. Included use of 4Ts score, lab testing and treatment pathways. HaemSTAR role: Led by Dr Richard Buka. Data collection coordinated via the trainee network. Size of study: National, multi-centre. Main outcomes: Preliminary finding: suboptimal diagnostic work-up in suspected HIT Outputs: Presented at National conference – BSH 2025 – poster. Ongoing analysis and future publication expected. MoM-ITP (Maternal ITP/neonatal outcomes) – began in March 2024. Type of study: Prospective, multi-centre national audit.

		• Topic: Management of delivery and neonatal monitoring in mothers with ITP. Comparison to international consensus guidelines. • HaemSTAR role: Co-led by Dr Nick Fordham and Dr Olga Tsiamita with HaemSTAR. Run and coordinator by the HaemSTAR network. Funding from Grifols (non-promotional grant). • Size of study: Target 100 patients. • Main outcomes: Data collection complete • Outputs: Publication expected ATOMM (Anticoagulation for ThrOmbosis in Multiple Myeloma) • Type of study: National, retrospective audit. • Topic: Audit of thromboprophylaxis in newly diagnosed myeloma in the UK. To help inform the evidence-based selection of thromboprophylactic agents for patients receiving first line myeloma treatment. • HaemSTAR role: Lead: Tom Bull and the ATOMM committee. Lead site: Cambridge University Hospitals. Project developed in conjunction with myeloma patients. Supported by HaemSTAR with project management by BiCOPS. Funded by Myeloma UK. • Size of study: >2000 patients • Main outcomes: Data collection ran from March to July 2025. Data cleaning completed December 2025. Hoping to present results during 2026. • Outputs: Data analysis underway A short questionnaire has followed on from this initial data collection. The survey is not limited to those involved in ATOMM, but was aimed at anyone who is regularly responsible for prescribing thromboprophylaxis for myeloma patients. TXA in Heavy Menstrual Bleeding with acute VTE • Type of study: Survey of clinician practice, observational data collection, future RCT development. • Topic: To evaluate the use of tranexamic acid in women with heavy menstrual bleeding and recent VTE. • HaemSTAR role: Lead by Dr Eman Hassan. No funding specified. Distributed by HaemSTAR. Data analysis – Dr Eman Hassan. No funding. • Size of study: 102 respondents • Main outcomes: Apixaban preferred anticoagulant for patients with HMB. Wide variation in practice re timing of TxA use; 35% prescribed it any time following initiation of anticoagulation, 12% delayed its use for 3 months; 8% would never give it. 47% of respondents advise to discontinue COCP following VTE (whilst treated with anticoagulants). 63% of respondents willing to participate in a study of TxA ≤ 4 weeks following VTE. • Outputs: Paper March 2025: Thrombosis Research: Disparities in menstrual bleeding management during acute venous thromboembolism treatment: A review of UK practice and a call for clinical studies HaemSTAR RAPIDO (A ‘Flash-Mob’ UK national audit of the use of Reversal Agents in Patients antlcoagulated with Direct Oral anticoagulants) • Type of study: Retrospective National Audit. • Topic: Compliance with BSH guidelines for the use of reversal agents in patients with major
--	--	---

		haemorrhage who are taking direct oral anticoagulants (DOACs). • HaemSTAR role: Conceived and developed by Dr Richard Buka (Stoke) and HaemSTAR. Run by HaemSTAR. Data management provided by BiCOPS. Funded by AstraZeneca and the Dudley Leukaemia Unit Appeal Fund. • Size of study: 2265 patients. • Main outcomes: 875 patients had GI haemorrhage, 1012 had ICH. Median age 81 years. Median time from bleed onset to reversal: 6.5 hours. Median time from last dose of anticoagulation to reversal: 16.0 hours. 1001 of 1253 non-ICH bleeds fulfilled criteria for major hemorrhage. Propensity score-matched analysis of 494 patients with GI haemorrhage: outcomes similar for andexanet alfa and four factor prothrombin complex concentrate. Incidence of stroke was significantly higher with andexanet alfa. • Outputs: Poster presentation at ASH Annual Congress 2024 and BSHT Annual Conference 2025. Paper in process within the above timeframe. Publication anticipated March 2026. Abstract published November 5th 2024. MATRON (Maternal Audit on ThRombolysis Outcome and DecisioN) - Survey • Type of study: UK Clinician Survey • Topic: The use of thrombolysis for pregnant women with venous thromboembolism. • Size of study: Survey with 70 responses. Target audit responses of 200 patients (completion Q2 2025). • HaemSTAR Role: Conceived and developed by Dr Giulia Simini (Royal London & HaemSTAR). Run by HaemSTAR. Data management by HaemSTAR. • Main outcomes: Survey: CDT available to 74%, Surgical thrombectomy to 62% and ECMO to 52% of respondents. Only 50% of sites had specific guidelines on CDT and 17% had no guidelines on managing pregnancy associated PE. 38% had received specific training on pregnancy-associated PE. 22% had had training in systemic thrombolysis. 46% did not have access to PERT with geographic inconsistency. Audit in planning stages. • Outputs: Survey manuscript published July 2025. In process within above timeframe. Abstract published 14th May 2024. MATRON – Audit • Type of study: Pan-UK audit. Retrospective. • Topic: Aiming to assess management of high risk and intermediate-high risk pulmonary embolism in pregnancy and puerperium. • Size of study: 75 cases. • HaemSTAR role: Conceived and developed by Dr Giulia Simini (Royal London & HaemSTAR). Run by HaemSTAR. Data management by HaemSTAR. • Main outcomes: data analysis ongoing. • Outputs: Further analysis ongoing as of May 2025. Planning a second window for data collection. Planning abstract submission for ISTH 2026. VAMP: Venesection vs Active Monitoring in Secondary Polycythaemia • Type of study: International clinician survey, retrospective audit and then prospective clinical trial.
--	--	--

		• Topic: Venesection in patients with idiopathic and secondary erythrocytosis • Size of study: Survey with 123 responses (90 senior clinicians). Audit with 206 patients. Prospective study in development. • HaemSTAR Role: Conceived and developed by Dr Richard Buka, Dr Bernard Maybury and Dr Pip Nicolson (Birmingham & HaemSTAR), Run by HaemSTAR, Data management by HaemSTAR. • Main outcomes: ○ Survey: minority venesect routinely, 2/3 will venesect in specific circumstances; 1/3 never venesect. More likely to venesect if previous thrombosis or if headache or visual disturbance. Majority use Hct threshold of 0.55 but some use 0.6 and most have Hct target of <0.55 but some use <0.52. 85% willing to consider entering patients into a trial. ○ Audit: 2360 patients screened, 206 eligible. 27% no EPO done. Minority have RCM scan done. Most given appropriate lifestyle advice. 60% never venesected. 29% of those venesected have no target Hct documented. Mean Hct reduces prior to diagnosis and further reduces regardless of venesection. 5 year thrombosis rate 12% regardless of venesection vs no venesection or whether polycythaemia resolves. Cancer and prior unprovoked VTE are the only factors to predict subsequent thrombosis. • Outputs: Audit poster presentation at BSH 2024. Manuscript accepted and predicted publication in June 2025. Anticoagulation at the end of life • Type of study: National survey • Topic: To gauge current practice and decision-making surrounding anticoagulation at the end of life. Hoping to pave the way for further research in the area. • Size of study: 186 responses. • HaemSTAR involvement: led by Dr Thomas Shevlin and Dr Olga Tsiamita. Distributed by HaemSTAR network. • Main outcomes: 56% of respondents routinely seek advice from colleagues regarding these decisions. 53% of respondents reported having worried about the medico-legal implications of discontinuing OAC, 52% of whom reported the worries influence their decision making. 83% would feel more confident in broaching this subject if national guidance existed. • Outputs: Publication: clinical medicine: Are we comfortable managing oral anticoagulation at the end of life? A national survey of secondary care clinicians in the UK In set up: Perioperative management of Haemophilia B 'FIX-Surg' The primary objectives of the project are to audit the haemostatic management of patients with haemophilia B who are undergoing surgery against World Federation of Haemophilia guidelines. Project running from April to June 2025. PaTRIC – Practice of Transfusion In Cirrhosis
--	--	---

		PaTRIC is the UK arm of an international audit evaluating real-world transfusion practices in hospitalised patients with cirrhosis, focusing on platelet and coagulation factor replacement. Anticipated data collection March to June 2026. TRUTH- sTeroids in warm aUTOimmune Haemolytic anaemia TRUTH is a UK-wide audit of the management of warm autoimmune haemolytic anaemia, focusing on corticosteroid use. Aiming to open in March 2026. AQuA- Acquired Haemophilia A – National Audit Acquired haemophilia A is a rare, potentially life-threatening bleeding disorder caused by autoantibodies against FVIII. There are national BSH guidelines for the 'Diagnosis and Management of Acquired Coagulation Factor Inhibitor' from 2013, and international consensus recommendations from 2020, but management options have changed considerably over this time and local practices across the UK differ. The HaemSTAR hub-and-spoke model is an ideal platform for looking at rare diseases. AQuA is a multicentre, national audit, comprising a 5-year retrospective review of patients diagnosed with acquired haemophilia A. We aim to include a minimum of 6 comprehensive care centres in the audit. FUNDING AWARDS From the ISTH London 2022 Legacy Fund we were able to fund travel grants for trainees attending conferences (e.g. EAHAD 2025) and the International fellowship programme (Nigeria collaboration). This enabled conference attendance, presentation of HaemSTAR work, professional development and ongoing international collaboration work. Awards were through competitive application with award by grant panel. Funding was obtained and used for specific research studies: - RAPIDO (Astra Zeneca and Dudley fund) - MOM-ITP (Grifols) - A2PLS (Bayer) This supported data management and study infrastructure. Charity income detailed below. CONFERENCE In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 10/2/25 at The Liner Hotel, Liverpool. This comprised updates and results on current HaemSTAR projects and plenary talks from experts on research in global health settings, 'blood is the heart of medicine' and National haemovigilance updates (SHOT). Very positive feedback. Attendance was free and was increased from the year before. Free registration for HaemSTAR conference helped with travel reimbursement to enable attendance as well supporting the invited speakers. HaemSTAR breakfast Briefings In collaboration with 'The Limbic' we provide monthly, free, online webinars led by experts with interactive Q&A segments. These are targeted at haematology trainees and consultants. They are predominantly focused on non-malignant haematology education and research translation. Topics in the last year have included VTE in pregnancy, genetic testing in haemostasis, iron deficiency, PNH and new therapies. The Limbic reimburse £5 to HaemSTAR for every attendee that fills in feedback surveys. PODCAST- Don't Just Read the Abstract Hosted by Dr Richard Buka and Dr Pip Nicolson, the focus of discussion is of recent research papers in non-
--	--	--

		malignant haematology, critical appraisal of evidence and expert guest interviews. The purpose of it is to help trainees go beyond abstracts – to understand methods, bias and clinical impact. BLOG HaemSTAR maintains a regular blog with contents which include conference reflections, trainee experiences, project updates, and thought pieces on collaboration and research. BSH CONFERENCE SESSION HaemSTAR delivered a dedicated session within the BSH 2025 programme. This included an overview of HaemSTAR, project presentations, how to get involved and research education. This raised awareness of ongoing HaemSTAR studies, research opportunities and encouraged new project proposals. HaemSTAR also had its own stall with promotion of current and upcoming studies, HaemSTAR events, signposting to website and project sign-up and networking with potential collaborators.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	N/A – not relevant to our charitable purposes

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	N/A
Policy on social investment including program related investment	Para 1.38	N/A
Contribution made by volunteers	Para 1.38	N/A
Other		N/A

Achievements and Performance

	SORP reference	
--	----------------	--

Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	FUNDING Received the following grants: - Research Grant from AstraZeneca UK for RAPIDO: £17,600 (part of previous £88,000 grant) - Research Grant from SOBI UK: for FIX-SURG £36,750 - Research Grant from Takeda for AcQa: £6,500 - Research Grant from SOBI UK: For Real world data in ITP project: £18,375 - Administrative support (unrestricted grant) from Takeda: £5,000 PUBLICATIONS • Nicolson PLR, Belete M, Hawes R, Fowler N, Toh CH. Alternative routes into clinical research: a guide for early career doctors. BMJ. 2024;385:e076414. • Hassan E, Sutton D, Buka RJ, Lowe GC, Nandra T, Jacob N, Rose L, Alhamdi Y, HaemSTAR Collaborators, Nicolson PLR. Disparities in Menstrual Bleeding Management During Acute Venous Thromboembolism Treatment: A Review of UK Practice and a Call for Clinical Studies. Thromb Res 2025 https://doi.org/10.1016/j.thromres.2025.109258
---	-----------	--

Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	Amount held at start of reporting period: £70,338 Income from all sources (including interest): £92,401 All spending: £47,130 Amount held at the end of the reporting period: £141,352
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Cash in bank at 31/5/24 was £70,338 in unrestricted funds and £25,742 in restricted funds for ISTH Legacy fund spending committed spending for 2024-25 comprises website hosting fees of approximately £350, podcast hosting fees of £200, accountancy fees of ~£150 and administration costs (paid for the time of our administrator) of ~£3000. This is all covered by the administrative grant of £5000 from Takeda and does not represent a financial risk. We also aim to apply for additional sponsorship of the podcast for when the Sobi sponsorship ends in 2025. In 2023-24 we expanded our ability to fund registrars to attend conferences. £19,200 of this comes from the ISTH Legacy fund and we are able to use this until 2026. It is unlikely that costs will exceed this figure. The educational webinars are a source of an approximately £1200 annual cost. This is voluntary however and can be stopped if there are insufficient funds. The HaemSTAR Update Day is now a recurring event but this is organised through Hartley Taylor and they secure industry support for the meeting. The only HaemSTAR costs are voluntary and will not go ahead if there are insufficient funds. All the projects currently active are fully funded. However we would like to run unfunded projects by using money underspent from other projects and also pump prime our pipeline by employing a project/data manager through the University of Birmingham at a cost of approximately £70,000 per year. This is not yet feasible and will not go ahead unless there are sufficient funds. The funding for this will be reviewed on an annual basis and no commitments beyond 1 year will be made to ensure there is no financial risk to the charity.
Amount of reserves held	Para 1.22	£0
Reasons for holding zero reserves	Para 1.22	We do not have a reserve policy.
Details of fund materially in deficit	Para 1.24	N/A
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	Nil uncertainties. N/A

Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any	Para 1.46	

social investment policy adopted		
A description of the principal risks facing the charity	Para 1.46	
Other		

Structure, Governance and Management

Description of charity's trusts:		Nil
Type of governing document (trust deed, royal charter)	Para 1.25	Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Unincorporated Association
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Nil.

Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and Administrative details

Charity name	HaemSTAR: Haematology Specialist Training, Audit and Research
Other name the charity uses	HaemSTAR
Registered charity number	1199224
Charity's principal address	Office 129, Institute of Biomedical Research Edgbaston Birmingham B15 2TT

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Phillip LR Nicolson	President		
2	Richard J Buka	Chair		
3	Andrew J Doyle			
4	Emily Millen			
5	Tom Bull			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Corporate trustees – names of the directors at the date the report was approved

[illegible]

Name of trustees holding title to property belonging to the charity

[illegible]

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	Nil
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	N/A
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	N/A

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

N/A


Other optional information

--

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr Phillip LR Nicolson	
Position (eg Secretary, Chair, etc)	President	
Date	27/3/2026	



Receipts and payments accounts

CC16a

For the period
from

01/06/2024

To

31/05/2025

Section A Receipts and payments

	Unrestricted funds	Restricted funds	Endowment funds	Total funds	Last year
	to the nearest £	to the nearest £	to the nearest £	to the nearest £	to the nearest £
A1 Receipts					
35-day Savings Interest (28/6/2024)	167	-	-	167	-
95-day Savings Interest (28/6/2024)	32	-	-	32	-
Business Reserve Interest (28/6/2024)	11	-	-	11	-
35-day Savings Interest (31/7/2024)	197	-	-	197	-
Business Reserve Interest (31/7/2024)	13	-	-	13	-
95-day Savings Interest (31/7/2024)	36	-	-	36	-
AstraZeneca UK Ltd (Unrestricted Research grant - RAPIDO 23/08/2024)	17,600	-	-	17,600	-
35-day Savings Interest (30/8/2024)	180			180	
30/08/2024)	8			8	
Bank interest (95-Day Account 30/08/2024)	31			31	
Limbic Digital (Webinar income 09/09/2024)	2,440			2,440	
PayPal (Donation – small 11/09/2024)	0			0	
Bank interest (35-Day Account 30/09/2024)	134			134	
Bank interest (95-Day Account 30/09/2024)	84			84	
Bank interest (Business Reserve 30/09/2024)	10			10	
S P Hibbs (Refund – overpayment 18/10/2024)	0			0	
Bank interest (35-Day Account 31/10/2024)	89			89	
Bank interest (Business Reserve 31/10/2024)	12			12	
Bank interest (95-Day Account 31/10/2024)	126			126	
Limbic Digital (Webinar donation income 08/11/2024)	70			70	
Bank interest (35-Day Account 29/11/2024)	80			80	
Bank interest (Business Reserve 29/11/2024)	11			11	
Bank interest (95-Day Account 29/11/2024)	118			118	
Bank interest (35-Day Account 31/12/2024)	89			89	
Bank interest (Business Reserve 31/12/2024)	12			12	
Bank interest (95-Day Account 31/12/2024)	131			131	
Swedish Orphan Biovitrum (SOBI UK) – sponsorship/grant (08/01/2025)	19,950			19,950	
Swedish Orphan Biovitrum (SOBI UK) – sponsorship/grant (17/01/2025)	18,375			18,375	
Takeda (via LLXEU/Payce) – sponsorship/grant (31/01/2025)	5,000			5,000	
Bank interest (35-Day Account 31/01/2025)	84			84	
Bank interest (Business Reserve 31/01/2025)	11			11	
Bank interest (95-day account 31/01/2025)	126			126	
Takeda (via LLXEU/Payce) – sponsorship/grant (28/02/2025)	6,500			6,500	
Swedish Orphan Biovitrum (SOBI UK) – sponsorship/grant (28/02/2025)	9,188			9,188	
Bank interest (35-Day Account 28/02/2025)	72			72	
Bank interest (Business Reserve 28/02/2025)	10			10	
Bank interest (95-Day Account 28/02/2025)	231			231	
Bank interest (35-Day Account 31/03/2025)	73			73	
Bank interest (Business Reserve 31/03/2025)	11			11	
Bank interest (95-Day Account 31/03/2025)	256			256	
Dr P Nicolson (Gift Aided donation 01/04/2025)	750			750	
Swedish Orphan Biovitrum (SOBI UK) – sponsorship/grant (25/04/2025)	9,188			9,188	
Bank interest (35-Day Account 30/04/2025)	15			15	
Bank interest (Business Reserve 30/04/2025)	10			10	
Bank interest (95-Day Account 30/04/2025)	249			249	
Helen Apperley (Meal deposits refund 01/05/2025)	350			350	
Bank interest (35-Day Account 30/05/2025)	14			14	
Bank interest (95-Day Account 30/05/2025)	249			249	
Bank interest (Business Reserve 30/05/2025)	9			9	
	-	1	-	-	-

Sub total (Gross income for AR)	92,401	-	-	92,401	54,928
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	92,401	-	-	92,401	54,928

A3 Payments

Squarespace (Web domain 6/6/24)	29	-	-	29	-
ISTH Legacy (Gullia Simini EHA 21/6/24)	-	352	-	352	-
Squarespace (Web domain 6/7/24)	29	-	-	29	-
Currys (Laptop for Administrator 8/7/24)	799	-	-	799	-
Squarespace (Website 06/08/2024)	29			29	
Nkem Jacob (ISTH Legacy Fund payment 09/08/2024)		1,500		1,500	
Squarespace (Website 06/09/2024)	29			29	
Mrs H C Apperley (Admin invoice 04/10/2024)	2,490			2,490	
Stephen Hibbs (Update Day – Nigeria Lemfi 04/10/2024)		598		598	
Squarespace (Website 07/10/2024)	29			29	
Richard Buka (Novartis Meeting Train Expenses 18/10/2024)	106			106	
Pip Nicolson (Novartis train expenses 18/10/2024)	84			84	
Jasmine Mak (ASH 2024 travel 8/10/2024)	1,413			1,413	
Stephen Hibbs (ISTH Legacy Fund - Aisha Oct 25/10/2024)		17		17	
Squarespace (Website 06/11/2024)	29			29	
Stephen Hibbs (ISTH Legacy Fund – Aisha Oct 22/11/2024)		17		17	
Walaa Saad (ISTH Legacy Fund payment 29/11/2024)		589		589	
Squarespace (Website 06/12/2024)	29			29	
HMRC (Corporation Tax 10/12/2024)	100			100	
Squarespace (Website – additional/annual? 16/12/2024)	19			19	
Squarespace (Website 06/01/2025)	29			29	
Troy-Barnes (ISTH-ASH Legacy Fund payment 13/01/2025)		902		902	
Stephen Hibbs (ISTH Legacy Fund – Aisha Dec 13/01/2025)		19		19	
Acast (Podcast hosting service 14/01/2025)	152			152	
HMRC (Corporation Tax 27/01/2025)	100			100	
Stephen Hibbs (ISTH Legacy Fund – Aisha Jan 31/01/2025)		19		19	
Squarespace (Website 06/02/2025)	29			29	
C Arts Bar, Hope St Liverpool (HaemSTAR update day drinks 11/02/2025)	80			80	
Mr Richard J Buka (ASH 2025 expenses - RAPIDO Presentation 21/02/2025)	1,943			1,943	
Chloe Merrion (ISTH Legacy Fund payment 24/02/2025)		728		728	
Amazon (update day speaker gifts (6 x £75 24/02/2025)	450			450	
Squarespace (Website 06/03/2025)	29			29	
Stephen Hibbs (ISTH Legacy Fund – Aisha Feb 10/03/2025)		20		20	
O Tsiamita (Update Day travel 2025 payment 14/03/2025)	195			195	
J Wolf (Update Day travel 2025 payment 14/03/2025)	153			153	
Stephen Hibbs (Update Day travel 2025 14/03/2025)	39			39	
Laura Knox (Update Day 2025 payment 14/03/2025)	111			111	
Cam Edmead (HaemTRIAL admin invoice 21/03/2025)	45			45	
Willows Accountancy (Invoice 5763 21/03/2025)	120			120	
Stephen Hibbs (ISTH Legacy – Aisha Mar 21/03/2025)		19		19	
University of Birmingham (Invoice 72142196 re RAPIDO 28/03/2025)	27,535			27,535	
Squarespace (Website 07/04/2025)	29			29	
BHR NHS Trust (M Egolum placement, ISTH Legacy 11/04/2025)		500		500	
C Crossette-Thumbiah (Update Day 2025 reimbursement 23/04/2025)	115			115	
Mrs H C Apperley (Admin invoice – Apr 2025 23/04/2025)	2,263			2,263	
Janine Collins (ISTH Legacy Fund payment 24/04/2025)		584		584	
Stephen Hibbs (ISTH Legacy Nigeria – for M Igolum 28/04/2025)		430		430	
Motel One (BSH P Nicolson hotel 28/04/2025)	257			257	
Ka Pao Glasgow (restaurant – BSH conference meal? 29/04/2025)	740			740	
U Bello (ISTH Legacy – Igolum hotel 01/05/2025)		65		65	
Stephen Hibbs (ISTH Legacy – Aisha Apr 01/05/2025)		18		18	
Amazon (BSH Dragons Den prizes 01/05/2025)	150	2		150	

Squarespace (Website 07/05/2025)	29			29	
TfL Oyster (M Igolum travel ISTH Legacy – London 09/05/2025)		20	-	20	-
TfL Oyster (M Igolum travel ISTH Legacy – London 12/05/2025)		10	-	10	-
Mrs H C Apperley (ISTH Legacy – Igolum accommodation 16/05/2025)		909	-	909	-
TfL Oyster (M Igolum travel ISTH Legacy – London 19/05/2025)		10	-	10	-
	-	-	-	-	-
Sub total	39,804	7,326	-	47,130	39,541

A4 Asset and investment purchases, (see table)					
	-	-	-	-	
	-	-	-	-	
Sub total	-	-	-	-	-

Total payments	39,804	7,326	-	47,130	39,541
-----------------------	---------------	--------------	----------	---------------	---------------

Net of receipts/(payments)	52,597	- 7,326	-	45,271	15,388
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	70,338	25,742	-	96,081	-
Cash funds this year end	122,935	18,416	-	141,351	15,388

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Money in bank account (31/5/25)	141,352	-	-
		-	-	-
		-	-	-
	Total cash funds	141,352	-	-
	(agree balances with receipts and payments account(s))	Agreement Error	Agreement Error	OK

	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B4 Assets retained for the charity's own use			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval
	P NICOLSON	

Independent examiner's report on the accounts

Section A

Independent Examiner's Report

Report to the trustees

Charity Name

HaemSTAR: Haematology Specialty Training, Audit and Research

On accounts for the year ended

31/05/2025

1199224

Set out on pages

Two to Four

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31 May 2025

Responsibilities and basis of report

As the charity's trustees, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination (other than that disclosed below *) which gives me cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act; or
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed:

Date:

23 March 2026

Name:

Mark Fellows (Willows Accountancy Ltd)

Relevant professional qualification(s) or body (if any):

Fellow Member of Association of Accounting Technicians

Address:

172 Watling Street, Bridgtown, Staffordshire, WS11 0BD

Section B**Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

Accounts



CHARITY COMMISSION
FOR ENGLAND AND WALES

Trustees' Annual Report for the period

From 1/6/2023 Period start date To 31/5/2024 Period end date

Charity name: HaemSTAR: Haematology Specialist Training, Audit and Research

Charity registration number: 1199224

Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To protect and preserve the health of patients suffering from haematological conditions by: - the promotion of clinical research into Non-Malignant Haematology in the United Kingdom, the causes, prevention and treatment of haematological conditions on terms that the results of such research will be published. - the advancement of education and training of junior doctors and haematologists to give them the skills to become the chief and principal investigators of the future.'
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	During 1/6/23 to 31/5/24 we conceived, developed, ran, supported and/or wrote up eighteen projects. All of these projects further our charitable objects because - they all require project management (which is used to train junior doctors and haematologists in how to be researchers and principal investigators) and - they ultimately result in the publication of research findings that benefit patients. Projects take several years to complete from the time of inception. Activities completed 1/6/23 to 31/4/23 are highlighted in red text. ITP Post COVID19 Vaccine Type of study: Retrospective Observational Study. Topic: Timing of onset, clinical characteristics, response to treatment and outcomes of patients with ITP developing following COVID19 vaccination. HaemSTAR role: Conceived and developed by Dr Quentin Hill (Leeds). Run and promoted by the ITP Forum and HaemSTAR. Data management provided by PHE. Funded by PHE. Size of study: Data collection completed in 2022. Size of Study: No results available as study yet to publish. Main outcomes: Data analysis ongoing. Outputs: yet to publish. ConNeCT: Type of study: Prospective Observational Study. Topic: Neurological, cognitive and neuropsychiatric complications of TTP.

		• HaemSTAR role: Conceived and developed by Dr Tina Dutt and Dr Rebecca Shaw (Liverpool). Run and promoted by the University of Liverpool and HaemSTAR. Data management provided by University of Liverpool. Funded by the Bayer Haemophilia Awards Programme. • Size of study: 211 patients and 50 healthy volunteers recruited. Patient recruitment completed Feb 2024. Data collection ongoing (planned completion Q1 2025). • Main outcomes: Interim analysis ongoing, likely complete Q1 2026. • Outputs: Yet to finish data collection A2PLS (Anticoagulation in Antiphospholipid Syndrome): • Type of study: Retrospective National Audit. • Topic: Compliance with BSH guidelines on management of antiphospholipid syndrome (APS). • HaemSTAR role: Conceived by Dr Deepa Arachchillage and Dr Christina Crossette-Thambiah (Imperial College). Developed and run in collaboration HaemSTAR. Data management provided by Imperial College. Funded by Bayer AG. • Size of study: Recruited 499 patients (Target 500) • Main outcomes: ○ Overall: 69% of patients anticoagulated with warfarin, 17% DOAC, 6% other, 8% not anticoagulated. ○ Triple Pos: 80% on warfarin. 10% DOACs. ○ Of those with arterial thrombosis: VKA 71%, DOAC 9%, other 19.6%. ○ Overall: 39% thrombosis recurrence over 10 years (Arterial recurrence more likely than venous). Triple vs dual vs single positive disease not predictive of recurrence ○ LAC most predictive marker of recurrence • Outputs: Oral Presentation at American Society of Hematology Annual Congress (New Orleans) Dec 2022 Manuscript in preparation, delayed due to some unforeseen devastating personal circumstances within the study steering group. BAT-X (Bleeding Assessment Tool in patients with X-linked agammaglobulinaemia [XLA]): • Type of study: Prospective Observational Study. • Topic: To establish whether patients with XLA have increased bleeding. • HaemSTAR role: Conceived, developed and run by Dr Pip Nicolson and Dr Chris Smith (Birmingham) and HaemSTAR. Data management provided by University of Birmingham. Funded by the British Heart Foundation (BHF). • Size of study: Recruited 42 patients • Main outcomes: Median ISTH-BAT Score of 1 (IQR 0-4). 14 participants had scores ≥ 4. Two of these had colitis, 3 patients were on antiplatelets / anticoagulants / NSAIDs. • Outputs: Manuscript in preparation 2SR (Two-Sample Rule Survey) • Type of study: Healthcare Practitioner Questionnaire
--	--	---

		• Topic: to establish attitudes towards and compliance with two (historic) sample rule in blood transfusion. • HaemSTAR role: Conceived by Dr Lorna Cain (Birmingham) and Dr Suzy Morton (Birmingham, NHSBT). Developed with the help of HaemSTAR. Data management provided by NHSBT. Funded by NHSBT. • Size of study: 209 responses across 22 hospitals. • Main outcomes: 96% aware of 2 sample rule in their hospital. 57% understand what the rule is. 55% understand the rationale for the rule. 60% admitted to going against the rule on more than one occasion. Non-compliant behaviour not associated with 2SR training or seniority. • Outputs: Oral Presentation at BSH ASM 2023. Manuscript in preparation. HaemSTAR RAPIDO (A 'Flash-Mob' UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants) • Type of study: Retrospective National Audit. • Topic: Compliance with BSH guidelines for the use of reversal agents in patients with major haemorrhage who are taking direct oral anticoagulants (DOACs). • HaemSTAR role: Conceived and developed by Dr Richard Buka (Stoke) and HaemSTAR. Run by HaemSTAR. Data management provided by BiCOPS. Funded by AstraZeneca and the Dudley Leukaemia Unit Appeal Fund. • Size of study: 2265 patients. • Main outcomes: 875 patients had GI haemorrhage, 1012 had ICH. Median age 81 years. Median time from bleed onset to reversal: 6.5 hours. Median time from last dose of anticoagulation to reversal: 16.0 hours. 1001 of 1253 non-ICH bleeds fulfilled criteria for major hemorrhage. Propensity score-matched analysis of 494 patients with GI haemorrhage: outcomes similar for andexanet alfa and four factor prothrombin complex concentrate. Incidence of stroke was significantly higher with andexanet alfa. • Outputs: Poster presentation at ASH Annual Congress 2024 and BSHT Annual Conference 2025. Manuscripts in preparation. MOM-ITP: Audit of management of neonatal ITP • Type of study: Prospective National Audit • Topic: Compliance with international consensus guidelines on management of pregnant women with ITP and neonatal ITP. • HaemSTAR role: Conceived and developed by dr Nick Fordham (Evelina Children's Hospital) and Dr Olga Tsiamita (Barts and HaemSTAR). Run by HaemSTAR. Data Management by HaemSTAR. Funded by Grifols. • Size of study: Target 100 patients. Recruitment ongoing (completion planned Q4 2025) • Main outcomes: data collection ongoing • Outputs: data collection ongoing TXA for HMB in acute VTE Tranexamic acid is an effective antifibrinolytic drug that can reduce heavy menstrual bleeding. Despite excellent safety data showing negligible increased risk of thrombosis across millions of patient years, its use in women with heavy menstrual bleeding who have a recent venous thromboembolic event remains controversial. The goal of this project is to work towards a pilot Randomised Control Trial.
--	--	---

		• Type of study: UK Clinician Survey • Topic: Clinical attitudes and practice towards use of tranexamic acid in female patients with menorrhagia who have previously experienced venous thromboembolism. • HaemSTAR role: Conceived and developed by Dr Eman Hassan (Birmingham and HaemSTAR). Distributed by HaemSTAR. Data analysis by Dr Hassan. Funding: nil. • Size of study: 102 respondents. • Main outcomes: Apixaban preferred anticoagulant for patients with HMB. Wide variation in practice re timing of TxA use; 35% prescribed it any time following initiation of anticoagulation, 12% delayed its use for 3 months; 8% would never give it. 47% of respondents advise to discontinue COCP following VTE (whilst treated with anticoagulants). 63% of respondents willing to participate in a study of TxA $\leq$ 4 weeks following VTE. • Outputs: Manuscript in preparation. • Type of study: Randomised Controlled Trial • Topic: Management of HMB in patients with VTE on anticoagulation. • HaemSTAR role: conceived and developed by Dr Eman Hassan (Birmingham and HaemSTAR) and Dr Gill Lowe (Birmingham and UK-TReN). • Progress: PICO submitted to UK NIHR HTA. Outcome awaited. MATRON (Maternal Audit on Thrombolysis Outcome and Decision) • Type of study: UK Clinician Survey & Retrospective Audit • Topic: The use of thrombolysis for pregnant women with venous thromboembolism. • Size of study: Survey with 70 responses. Target audit responses of 200 patients (completion Q2 2025). • HaemSTAR Role: Conceived and developed by Dr Giulia Simini (Royal London & HaemSTAR). Run by HaemSTAR. Data management by HaemSTAR. • Main outcomes: Survey: CDT available to 74%, Surgical thrombectomy to 62% and ECMO to 52% of respondents. Only 50% of sites had specific guidelines on CDT and 17% had no guidelines on managing pregnancy associated PE. 38% had received specific training on pregnancy-associated PE. 22% had had training in systemic thrombolysis. 46% did not have access to PERT with geographic inconsistency. Audit in planning stages. • Outputs: Survey manuscript in preparation. VAMP: Venesection vs Active Monitoring in Secondary Polycythaemia • Type of study: International clinician survey, retrospective audit and then prospective clinical trial. • Topic: Venesection in patients with idiopathic and secondary erythrocytosis • Size of study: Survey with 123 responses (90 senior clinicians). Audit with 206 patients. Prospective study in development. • HaemSTAR Role: Conceived and developed by Dr Richard Buka, Dr Bernard Maybury and Dr Pip Nicolson (Birmingham & HaemSTAR), Run by HaemSTAR, Data management by HaemSTAR. • Main outcomes:
--	--	---

		○ Survey: minority venesect routinely, 2/3 will venesect in specific circumstances; 1/3 never venesect. More likely to venesect if previous thrombosis or if headache or visual disturbance. Majority use Hct threshold of 0.55 but some use 0.6 and most have Hct target of <0.55 but some use <0.52. 85% willing to consider entering patients into a trial. ○ Audit: 2360 patients screened, 206 eligible, 27% no EPO done. Minority have RCM scan done. Most given appropriate lifestyle advice. 60% never venesected. 29% of those venesected have no target Hct documented. Mean Hct reduces prior to diagnosis and further reduces regardless of venesection. 5 year thrombosis rate 12% regardless of venesection vs no venesection or whether polycythaemia resolves. Cancer and prior unprovoked VTE are the only factors to predict subsequent thrombosis. • Outputs: Audit poster presentation at BSH 2024. Survey and Audit: manuscript in preparation. In set up: Apixaban thrombo-prophylaxis in multiple myeloma It is recommended that multiple myeloma patients treated with IMiDs such as thalidomide and lenalidomide be offered prophylactic anticoagulation due to the high risk of VTE. We understand that practice in the UK has shifted considerably and despite a lack of evidence, clinicians now favour the use of oral factor anti-Xa inhibitors, often apixaban, for this purpose. The aim of this project is to perform a retrospective, observational study to document thrombosis and bleeding outcomes in patients who receive this treatment compared to those who receive low molecular weight heparin. • Progress: Awaiting outcome of Myeloma UK grant application (as of 31/5/24) Anticoagulation at the end of life A survey is to gather data from secondary care clinicians in the UK on their management of anticoagulation in patients at the end of life. Perioperative management of Haemophilia B 'FIX-Surg' The primary objectives of the project are to audit the haemostatic management of patients with haemophilia B who are undergoing surgery against international guidelines (Srivastava et al., 2020). An Epidemiological Survey of Morbidity and Mortality in Patients Over the Age of 35 With Thalassaemia (Transfusion Dependent and Non-Transfusion Dependent) in England: SUMMIT Thalassaemia has historically been a severely life limiting disease with significant comorbid complications from an early age. As treatments, monitoring and awareness of this condition improve, so does quality of life and life expectancy. This study aims to assess whether patients over the age of 35 with thalassaemia are monitored in keeping with national guidelines, and to build a picture of the co-morbidities affecting patients with both transfusion and non-transfusion dependent thalassaemia over the age of 35 in the United Kingdom. FUNDING AWARDS From the ISTH Legacy Fund we were able to fund the conference attendances (see website for awardees).
--	--	--

		Application for award through competitive application with award by grant panel. Part of the ISTH Legacy Fund was to promote collaboration with LMIC (Nigeria) and help them develop their own trainee research network. In collaboration with NSHBT (Nigerian Society for Haematology and Blood Transfusion) they have founded HaemRYNE. Funds go towards infrastructure development and travel costs to promote educational visits within Nigeria and to UK. CONFERENCE In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 5/2/24 at Austin Court in Birmingham. This comprised updates and results on current HaemSTAR projects, plenary talks from experts including reflections on clinical/academic careers, management of HMB, CRISPR-Cas9, rural haematology as well as discussions about the role of the NIHR HTA. Very positive feedback. increased industry engagement from previous year. Increased attendance. Free registration HaemSTAR helped with travel reimbursement to enable attendance as well the time of the invited speakers. DISEASE THEMED WEBINARS Teamed up with 'The Limbic' to provide monthly online webinars from KOLs providing thought provoking and educational talks on disparate areas of non-malignant haematology. KOLs are reimbursed for their time. The Limbic reimburse HaemSTAR if attendees fill in feedback surveys. PODCAST Received funding from Sobi to purchase equipment and fund external agency to provide sound engineering expertise. Monthly journal club podcast on latest papers in non-malignant haematology. Includes author interviews and discussion with experts. BSH CONFERENCE SESSION HaemSTAR now has a session at BSH (in association with UK-TReN) in the form of Dragon's Den. HaemSTAR funded the prizes in this session.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	N/A – not relevant to our charitable purposes

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	N/A
Policy on social investment including program related investment	Para 1.38	N/A
Contribution made by volunteers	Para 1.38	N/A

Other		N/A

Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	FUNDING Received the following grants: - Legacy fund from 2022 ISTH conference in London (see above): £28,810. - Podcast support (unrestricted educational grant) from Sobi: £19,200 - Administrative support (unrestricted grant) from Takeda: £5,000 PUBLICATIONS Nicolson PLR, Belete M, Hawes R, Fowler N, Toh CH. Alternative routes into clinical research: a guide for early career doctors. BMJ. 2024;385:e076414.

Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	Amount held at start of reporting period: £80,693 Income from all sources (including interest): £54,928 All spending: £39,541 Amount held at the end of the reporting period: £96,081
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Cash in bank at 31/5/24 was £69,598 in unrestricted funds and £26,492 in restricted funds for ISTH Legacy fund spending committed spending for 2024-25 comprises website hosting fees of approximately £350, podcast hosting fees of £200, accountancy fees of ~£150 and administration costs (paid for the time of our administrator) of ~£3000. This is all covered by the administrative grant of £5000 from Takeda and does not represent a financial risk. We also aim to apply for additional sponsorship of the podcast for when the Sobi sponsorship ends in 2025. In 2023-24 we expanded our ability to fund registrars to attend conferences. £19,200 of this comes from the ISTH Legacy fund and we are able to use this until 2026. It is unlikely that costs will exceed this figure. The educational webinars are a source of an approximately £1200 annual cost. This is voluntary however and can be stopped if there are insufficient funds. There is an approximate £30,000 cost still associated with RAPIDO that is waiting to be paid to the University of Birmingham but this is covered by the Astra Zeneca grant from last year. The HaemSTAR Update Day is now a recurring event but this is organised through Hartley Taylor and they secure industry support for the meeting. The only HaemSTAR costs are voluntary and will not go ahead if there are insufficient funds. All the projects currently active are fully funded. However we would like to run unfunded projects by using money underspent from other projects and also pump prime our pipeline by employing a project/data manager through the University of Birmingham at a cost of approximately £70,000 per year. This is not yet feasible and will not go ahead unless there are sufficient funds. The funding for this will be reviewed on an annual basis and no commitments beyond 1 year will be made to ensure there is no financial risk to the charity.
Amount of reserves held	Para 1.22	£0
Reasons for holding zero reserves	Para 1.22	We do not have a reserve policy.
Details of fund materially in deficit	Para 1.24	N/A
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	Nil uncertainties. N/A

Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	

Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	
Other		

Structure, Governance and Management

Description of charity's trusts:		Nil
Type of governing document (trust deed, royal charter)	Para 1.25	Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Unincorporated Association
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Nil.

Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and Administrative details

Charity name	HaemSTAR: Haematology Specialist Training, Audit and Research
Other name the charity uses	HaemSTAR
Registered charity number	1199224
Charity's principal address	Office 129, Institute of Biomedical Research Edgbaston Birmingham B15 2TT

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Phillip LR Nicolson	President		
2	Richard J Buka	Chair		
3	Andrew J Doyle			
4	Emily Millen			
5	Tom Bull			
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Corporate trustees – names of the directors at the date the report was approved

[illegible]

Name of trustees holding title to property belonging to the charity

[illegible]

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	Nil
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	N/A
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	N/A

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

N/A


Other optional information

--

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Dr Phillip LR Nicolson	
Position (eg Secretary, Chair, etc)	President	
Date	21/3/2025	



CHARITY COMMISSION
FOR ENGLAND AND WALES

HaemSTAR: Haematology Specialty Training Audit and
Research

1199224

Receipts and payments accounts

CC16a

For the period from	01/06/2023	To	31/05/2024
------------------------	------------	----	------------

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
ISTH Legacy Fund Award 30/6/2023		28 810	-	28 810	35 200
Sobi Podcast Sponsorship 12/12/2023 (inv 20231129 Sobi Podcasts)	19 200	-	-	19 200	17 600
35-day Savings Interest (29/12/23)	103			103	
Takeda Non-specific grant 9/1/24	5 000	-	-	5 000	-
35-day Savings Interest (31/01/24)	197			197	
35-day Savings Interest (29/02/24)	174			174	
Business Reserve Interest 29/2/24	1			1	
35-day Savings Interest (28/3/24)	168			168	
Business Reserve Interest 28/3/24	11			11	
95-day Savings Interest (28/3/24)	32			32	
Business Reserve Interest 30/4/24	13			13	
35-day Savings Interest (30/4/24)	199			199	
95-day Savings Interest (30/4/24)	38			38	
Business Reserve Interest 31/5/24	12			12	
35-day Savings Interest (31/5/24)	185			185	
95-day Savings Interest (31/5/24)	36			36	
Pip Nicolson (Charitable Donation) 2/4/24	750	-	-	750	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	26 118	28 810	-	54 928	52 800
A2 Asset and investment sales, (see table).					
	-	-	-	-	
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	26 118	28 810	-	54 928	52 800

A3 Payments

Squarespace (Web domain) 6/6/2023	19	-	-	19	23
University of Birmingham (RAPIDO 1 inv 71049181) 16/6/2023	20 000	-	-	20 000	268
Squarespace (Web domain) 6/7/2023	19	-	-	19	2 786
Squarespace (Web domain) 6/8/2023	19	-	-	19	240
RCPATH (Podcast CPD Accreditation) 14/8/2023	250	-	-	250	543
Squarespace (Web domain) 6/9/2023	19	-	-	19	45
Rich Buka (Ableton Software for Podcast) 12/9/2023	129	-	-	129	155
University of Birmingham (RAPIDO 2 inv 71345158) 6/10/2023	10 000	-	-	10 000	189
Squarespace (Web domain) 6/10/2023	19			19	82
Amazon (Ian Roberts, Limbic Webinar Thank you Payment 6/10/2023)	100			100	338
Squarespace (Web domain) 6/11/2023	19			19	19
Amazon (Noemi Roy, Limbic Webinar Thank you Payment 27/11/2023)	100			100	19
Squarespace (Web domain) 6/12/2023	19			19	19
Squarespace (Web domain) 8/1/2024	19			19	26
Helen Apperley (Jun 23-Jan 24 Admin support, 90 hrs at £15 ph) 15/1/24	1 350			1 350	250
Maryam Subhan (ISTH Legacy Fund, 15/1/24)		1 418		1 418	19
Acast (Podcast hosting annual fee, 2023-2024)	145			145	
Amazon (audio equipment for podcast: XLR microphone cable) 24/1/24	11			11	
Amazon (Audio equipment for podcast: condenser microphone, pop filter, mic stand, 25/1/24)	382			382	
Amazon (Mark Thomas & Sutesh Sivapalaratnam, Limbic Webinar Thank you Payments x2 29/1/24)	200			200	
Squarespace (Web domain) 6/2/2024	19			19	
Amazon (Angela Weyland HaemSTAR update day speaker thank you payment 20/2/24)	150			150	
Amazon (Dan Hart, A Rutherford, Sophie Evans, M Badat. HaemSTAR update day speaker thank you payments x4 26/2/24)	400			400	
Squarespace (Web domain) 26/2/2024	3			3	
Squarespace (Web domain) 6/3/24	29			29	
Olga Tsiamita (HaemSTAR update day travel. 13/3/24)	177			177	
J Schofield (HaemSTAR update day travel. 13/3/24)	126			126	
Julia Wolf (HaemSTAR update day travel. 13/3/24)	174			174	
Stephen Hibbs (HaemSTAR update day travel. 13/3/24)	57			57	
Helen Apperley (postage reimbursement. 13/3/24)	14			14	
Giulia Simini (HaemSTAR update day travel. 13/3/24)	147			147	
Ethan Troy-Barnes (HaemSTAR update day travel. 13/3/24)	134			134	
Catrin Cox (BSH Travel 13/3/24)	120			120	
Christina Crossette-Thambiah (BSH Travel 13/3/24)	120			120	
Joe Apperley (Podcast editing x2 episodes) 26/3/24	680			680	
Amazon (Tom Bullock, Limbic webinar thank you payment)	100			100	
Squarespace (Web domain) 7/3/2024	29			29	

John Chadwick (ISTH Legacy Fund) 5/4/2024		750		750	
Willows Accountancy (Preparation of Annual Accounts) 5/4/2024	120			120	
Squarespace (Web domain) 8/4/2024	29			29	
BACARO, Liverpool (BSH Reps Meal) 30/4/24	420			420	
Amazon (Richard Riley & Bernard Laemmle, Limbic Webinar Thank you Payments x2 20/05/2024)	200			200	
Gill Lowe (BSH Session Prize reimbursement, 28/5/24)	100			100	
Elena Torre (ISTH Legacy Fund, BSH 28/5/24)		500		500	
Richard Buka (BSH Hotel/Travel, 28/5/24)	107			107	
Lottie Hickman (BSH Hotel/Travel, 28/5/24)	198			198	
Yen Huan Yeo (ISTH Legacy Fund, BSHT 28/5/24)		400		400	
		-	-	-	-
Sub total	36 473	3 068	-	39 541	5 022

A4 Asset and investment purchases, (see table)					
	-	-	-	-	
	-	-	-	-	
Sub total	-	-	-	-	-

Total payments	36 473	3 068	-	39 541	5 022
-----------------------	---------------	--------------	----------	---------------	--------------

Net of receipts/(payments)	- 10 355	25 742	-	15 388	47 778
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	80 693	-	-	80 693	-
Cash funds this year end	70 338	25 742	-	96 081	47 778

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Money in bank account (31.5.24)	96 081	-	-
		-	-	-
		-	-	-
	Total cash funds	96 081	-	-
	(agree balances with receipts and payments account(s))	Agreement Error	Agreement Error	OK

	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B4 Assets retained for the charity's own use			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature	Print Name	Date of approval



CHARITY COMMISSION
FOR ENGLAND AND WALES

Independent examiner's report on the accounts

Section A

Independent Examiner's Report

Report to the trustees

Charity Name

Haemstar: Haematology Speciality Training Audit and Research

On accounts for the year ended

31/05/2024

Charity no
(if any)

1199224

Set out on pages

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31 May 2024.

Responsibilities and basis of report

As the charity's trustees, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act; or
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Mark Fellows

Date:

18 March 2025

Name:

Mark Fellows (Willows Accountancy Ltd)

Relevant professional
qualification(s) or body
(if any):

Fellow Member of Association of Accounting Technicians

Address:

172 Watling Street, Bridgtown, Staffordshire, WS11 0BD

Section B**Disclosure**

Only complete if the examiner needs to highlight material matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

Accounts



CHARITY COMMISSION
FOR ENGLAND AND WALES

Independent examiner's report on the accounts

Section A

Independent Examiner's Report

Report to the trustees

Charity Name

Haemstar: Haematology Speciality Training Audit and Research

**On accounts for the year
ended**

31/05/2023

**Charity no
(if any)**

1199224

Set out on pages

2 to 3

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 31 May 2023.

**Responsibilities and
basis of report**

As the charity's trustees, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent
examiner's statement**

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act; or
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Mark Fellows

Date:

13 March 2024

Name:

Mark Fellows (Willows Accountancy Ltd)

**Relevant professional
qualification(s) or body
(if any):**

Fellow Member of Association of Accounting Technicians

Address:

172 Watling Street, Bridgtown, Staffordshire, WS11 0BD



Receipts and payments accounts

For the period
from

01/04/2022

To

31/05/2023

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
AstraZeneca (RAPIDO Milestone 1&2) 18.11.22	35,200	-	-	35,200	-
AstraZeneca (RAPIDO Milestone 3) 28.11.22	17,600	-	-	17,600	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	52,800	-	-	52,800	-
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	52,800	-	-	52,800	-
A3 Payments					
Instant Print (Promotional flyers 1.4.22)	23	-	-	23	-
ISTH Membership and Conference Registration for Giulia Simini (3.5.22)	268	-	-	268	-
Wiley. Open access fees for Bull et al. JTH 2022 (4.5.22)	2,786	-	-	2,786	-
ISTH Conference Registration for Allie Delaney (21.6.22)	240	-	-	240	-
Conference Clearance Center (Open Access fees for Wilson et al. Hemasphe 2022, 15.7.22)	543	-	-	543	-
Vistaprint (30.9.22)	45	-	-	45	-
Total Merch (Promotional Pens etc, 18.1.23)	155	-	-	155	-
Rich Buka Expenses (roller poster, 1.3.23)	189	-	-	189	-
Lorna Cain (hotel and subsistance, HaemSTAR meeting newcastle 3.3.23)	82	-	-	82	-
Rich Buka Reimbursement for T-shirt purchase and Hotel Costs (HaemSTAR meeting 3.3.23)	338	-	-	338	-
Domain renting (Squarespace 6.3.23)	19	-	-	19	-
Website management (Squarespace 7.3.23)	19	-	-	19	-
Domain renting (Squarespace 6.4.23)	19	-	-	19	-
Rich Buka (BSH RAPIDO Poster 19.4.23)	26	-	-	26	-
UK SHEENA (BSH Regional Rep Meal Out 24.4.23)	250	-	-	250	-
Domain renting (Squarespace 9.5.23)	19	-	-	19	-
Sub total	5,022	-	-	5,022	-
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	5,022	-	-	5,022	-
Net of receipts/(payments)	47,778	-	-	47,778	-
A5 Transfers between funds	-	-	-	-	-

A6 Cash funds last year end	32,915	-	-	32,915	-
Cash funds this year end	80,693	-	-	80,693	-

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Money in bank account (31.5.23) Total cash funds (agree balances with receipts and payments account(s))	80,693 - - 80,693 OK	- - - - OK	- - - - OK
B2 Other monetary assets	Details	- - - - - - -	- - - - - - -	- - - - - - -
B3 Investment assets	Details	Fund to which asset belongs	Cost (optional) - - - - -	Current value (optional) - - - - -
B4 Assets retained for the charity's own use	Details	Fund to which asset belongs	Cost (optional) - - - - - - - - -	Current value (optional) - - - - - - - - -
B5 Liabilities	Details	Fund to which liability relates	Amount due (optional) - - - - -	When due (optional)
Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval	

Trustees' Annual Report for the period

Period start date		Period end date	
From	1 April 2022	To	31 May 2023

Section A Reference and administration details

Charity name

HaemSTAR: Haematology Specialist Training, Audit and Research

Other names charity is known by

HaemSTAR

Registered charity number (if any)

1199224

Charity's principal address

Office 129, Institute of Biomedical Research

Edgbaston

Birmingham

Postcode

B15 2TT

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Phillip LR Nicolson	President		
2	Richard J Buka	Chair		
3	Andrew J Doyle	Past-President		
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name	Dates acted if not for whole year
Emily Millen	
Tom Bull	

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Section B Structure, governance and management

Description of the charity's trusts

Type of governing document (eg. trust deed, constitution)	Constitution
How the charity is constituted (eg. trust, association, company)	Unincorporated Association
Trustee selection methods (eg. appointed by, elected by)	Appointed by existing trustees

Additional governance issues (Optional information)

You **may choose** to include additional information, where relevant, about:

- policies and procedures adopted for the induction and training of trustees;
- the charity's organisational structure and any wider network with which the charity works;
- relationship with any related parties;
- trustees' consideration of major risks and the system and procedures to manage them.

--

Section C Objectives and activities

Summary of the objects of the charity set out in its governing document

1. To protect and preserve the health of patients suffering from haematological conditions by:
 - a. the promotion of clinical research into Non-Malignant Haematology in the United Kingdom, the causes, prevention and treatment of haematological conditions on terms that the results of such research will be published.
 - b. the advancement of education and training of junior doctors and haematologists to give them the skills to become the chief and principal investigators of the future.'

Summary of the main activities undertaken for the public benefit in relation to these objects (include within this section the statutory declaration that trustees have had regard to the guidance issued by the Charity Commission on public benefit)

During 1/4/22 to 31/3/23 we conceived, developed, ran, supported and/or wrote up fourteen projects. All of these projects further our charitable objects because 1) they all require project management (which is used to train junior doctors and haematologists in how to be researchers and principal investigators) and 2) they ultimately result in the publication of research findings that benefit patients. Projects take several years to complete from the time of inception. Activities completed 1/4/22 to 31/3/23 are highlighted in red text.

CA-COVID19 (Coagulation Abnormalities in COVID19)

- **Type of study:** Retrospective Observational Study.
- **Topic:** Laboratory coagulation results and thrombotic and bleeding complications of patients admitted with COVID-19
- **HaemSTAR role:** Conceived and developed by Dr Deepa Arachchillage from Imperial College in association with HaemSTAR. Promoted by HaemSTAR. Run utilising the HaemSTAR network. Data management performed by Imperial College. Funded by Bayer.
- **Size of study:** Data collection completed 2021 (370 collaborators, 26 sites, 5883 patients).
- **Main outcomes:** Patients taking oral anticoagulation at time of diagnosis were more likely to be admitted to the intensive care unit (ICU). Patients developing thrombosis, major haemorrhage or multi-organ failure had a higher mortality. There was no difference in thrombosis rates or mortality between pregnant and non-pregnant women.
- **Outputs:** Two publications in Brit J Haem (Crossette-Thambiah et al. 2021, Arachchillage et al. 2022). Further publication in Rheumatology (see 'Achievements' below)

ITP Post COVID19 Vaccine

- **Type of study:** Retrospective Observational Study.
- **Topic:** Timing of onset, clinical characteristics, response to treatment and outcomes of patients with ITP developing following COVID19 vaccination.
- **HaemSTAR role:** Conceived and developed by Dr Quentin Hill (Leeds). Run and promoted by the ITP Forum and HaemSTAR. Data management provided by PHE. Funded by PHE.
- **Size of study:** Data collection completed in 2022.
- **Size of Study:** No results available as study yet to publish.
- **Main outcomes:** Data analysis ongoing.
- **Outputs:** yet to publish.

ConNeCT:

- **Type of study:** Prospective Observational Study.
- **Topic:** Neurological, cognitive and neuropsychiatric complications of TTP.
- **HaemSTAR role:** Conceived and developed by Dr Tina Dutt and Dr Rebecca Shaw (Liverpool). Run and promoted by the University of Liverpool and HaemSTAR. Data management provided by University of Liverpool. Funded by the Bayer Haemophilia Awards Programme.
- **Size of study:** Target of 200 patients and 50 healthy volunteers. Data collection ongoing (planned completion Feb 2024). 247 patients recruited as of 24/1/24.
- **Main outcomes:** Yet to finish data collection.
- **Outputs:** Yet to finish data collection.

A²PLS (Anticoagulation in Antiphospholipid Syndrome):

- **Type of study:** Retrospective National Audit.

- **Topic:** Compliance with BSH guidelines on management of antiphospholipid syndrome (APS).
- **HaemSTAR role:** Conceived by Dr Deepa Arachchillage and Dr Christina Crossette-Thambiah (Imperial College). Developed and run in collaboration HaemSTAR. Data management provided by Imperial College. Funded by Bayer AG.
- **Size of study:** Recruited 499 patients (Target 500)
- **Main outcomes:**
 - o Overall: 69% of patients anticoagulated with warfarin, 17% DOAC, 6% other, 8% not anticoagulated.
 - o Triple Pos: 80% on warfarin. 10% DOACs.
 - o Of those with arterial thrombosis: VKA 71%, DOAC 9%, other 19.6%.
 - o Overall: 39% thrombosis recurrence over 10 years (Arterial recurrence more likely than venous)
 - o Triple vs dual vs single positive disease not predictive of recurrence
 - o LAC most predictive marker of recurrence
- **Outputs:** Oral Presentation at American Society of Hematology Annual Congress (New Orleans) Dec 2022 (See 'Achievements' below) and Post-ISTH/ASH Conference (Newcastle) Feb 2023. Manuscript in preparation.
-

Vaccine Induced Thrombosis with Thrombocytopenia (VITT) Identification:

- **Type of study:** Retrospective Observational Study.
- **Topic:** Whether cases of VITT could be identified from routinely collected hospital admission and outcome data.
- **HaemSTAR role:** Conceived, developed and run by Dr Emily Millen (Nottingham) and Dr Andy Doyle (Kings College London), PHE and HaemSTAR. Data management and statistical analysis performed by PHE. No significant costs or funding.
- **Size of study:** Completed data collection 2022. (257 patients across 43 hospitals).
- **Main outcomes:** 14% of 84 patients admitted with VTE post ChAdOx1 or BNT162b2 mRNA vaccination had VITT. Attributable risk estimates for a cerebral venous thrombosis (CVT) or other VTE with thrombocytopenia after a first dose of ChAdOx1 vaccine were 2.82 and 9.62 per million doses respectively. However, elevated risks were also found after a first dose of ChAdOx1 for VTE without thrombocytopenia with relative incidences for CVT and other VTE of 2.67 (1.77–3.77) and 1.93 (1.57–2.35) respectively.
- **Outputs:** Published in Vaccine (See 'Achievements')
-

BAT-X (Bleeding Assessment Tool in patients with X-linked agammaglobulinaemia [XLA]):

- **Type of study:** Prospective Observational Study.
- **Topic:** To establish whether patients with XLA have increased bleeding.
- **HaemSTAR role:** Conceived, developed and run by Dr Pip Nicolson and Dr Chris Smith (Birmingham) and HaemSTAR. Data management provided by University of Birmingham. Funded by the British Heart Foundation (BHF).
- **Size of study:** Target recruitment: 50 patients. Recruitment ongoing until end of 2023. 43 patients recruited as of 31/3/23.
- **Main outcomes:** Yet to finish data collection.
- **Outputs:** Yet to finish data collection.

2SR (Two-Sample Rule Survey)

- **Type of study:** Healthcare Practitioner Questionnaire
- **Topic:** to establish attitudes towards and compliance with two- (historic) sample rule in blood transfusion.
- **HaemSTAR role:** Conceived by Dr Lorna Cain (Birmingham) and Dr Suzy Morton (Birmingham, NHSBT). Developed with the help of HaemSTAR. Data management to be provided by NHSBT. Funded by NHSBT.
- **Size of study:** 209 responses across 22 hospitals.
- **Main outcomes:** 96% aware of 2 sample rule in their hospital. 57% understand what the rule is. 55% understand the rationale for the rule. 60% admitted to going against the rule on more than one occasion. Non-compliant behaviour not associated with 2SR training or seniority.
- **Outputs:** Oral Presentation at BSH ASM 2023 (see 'Achievements'). Manuscript in preparation.

HaemSTAR RAPIDO (A 'Flash-Mob' UK national audit of the use of Reversal Agents in Patients anticoagulated with Direct Oral anticoagulants)

- **Type of study:** Retrospective National Audit.
- **Topic:** Compliance with BSH guidelines for the use of reversal agents in patients with major haemorrhage who are taking direct oral anticoagulants (DOACs).
- **HaemSTAR role:** Conceived and developed by Dr Richard Buka (Stoke) and HaemSTAR. To be run by HaemSTAR. Data management to be provided by BiCOPS. Funded by AstraZeneca and the Dudley Leukaemia Unit Appeal Fund. Not yet started recruiting.
- **Size of study:** Round 1: 837 patients (target 600). Round 2 scheduled for Autumn 2023 (also target of 600 patients).
- **Main outcomes:** Median age 81 years. 84% had atrial fibrillation and 18% had a history of venous thromboembolism. 778 (93%) fulfilled the study criteria for major haemorrhage. 431 (51%) had intracranial haemorrhage, 269 (32%) gastrointestinal bleeding, and 137 (16%) had bleeding at other sites. 448 (53%) patients were taking apixaban, 260 (31%) rivaroxaban, 77 (9%) edoxaban, and 52 (6%) dabigatran. 414 (49%) received Octaplex, 327 (39%) Beriplex, 49 (6%) andexanet alfa, and 47 (6%) idarucizumab. Median times to administration of a reversal agent were: from last dose of anticoagulation (where known) 15.8 h (IQR 9.8–23.3), from bleed onset 6.3 h (IQR 3.3–12.5), and from admission (in those who were outpatients at bleed onset) 4.3 h (IQR 2.1–7.9). At 90 days postadministration of any reversal agent, 350 (41%) patients had died and 33 (4%) had had a thrombotic events.
- **Outputs:** Poster presentation at BSH ASM 2023 (see 'Achievements').

AIHA Epi (The epidemiology of autoimmune haemolytic anaemia post COVID19 and COVID19 vaccination)

- **Type of study:** Retrospective Observational Study
- **Topic:** Epidemiology of autoimmune haemolytic anaemia (AIHA) in the post-COVID19 era.
- **HaemSTAR role:** Conceived by Dr Quentin Hill (Leeds). Developed by Dr Mohammed Altohami (Leicester) and HaemSTAR. To be run by HaemSTAR. Data management to be supported by PHE. Funded by PHE.
- **Size of study:** N/A
- **Main outcomes:** Study stopped due to lack of feasibility
- **Outputs:** Study stopped due to lack of feasibility

In set up:

TXA for HMB in acute VTE

Tranexamic acid is an effective antifibrinolytic drug that can reduce heavy menstrual bleeding. Despite excellent safety data showing negligible increased risk of thrombosis across millions of patient years, its use in women with heavy menstrual bleeding who have a recent venous thromboembolic event remains controversial. The goal of this project is to 1) survey clinicians to understand current practice, 2) gather observational data, and 3) work towards a pilot Randomised Control Trial.

MATRON (Maternal Audit on ThRombolysis Outcome and DecisioN)

Will look at the use of thrombolysis for pregnant women with venous thromboembolism. The aims of the project are to 1) survey clinicians to understand their current practice, and 2) gather observational data.

Apixaban thrombo-prophylaxis in multiple myeloma

It is recommended that multiple myeloma patients treated with IMiDs such as thalidomide and lenalidomide be offered prophylactic anticoagulation due to the high risk of VTE. We understand that practice in the UK has shifted considerably and despite a lack of evidence, clinicians now favour the use of oral factor anti-Xa inhibitors, often apixaban, for this purpose. The aim of this project is to perform a retrospective, observational study to document thrombosis and bleeding outcomes in patients who receive this treatment compared to those who receive low molecular weight heparin.

Patient-led research in sickle cell disease

We have formed a working group to develop project ideas in sickle cell disease based on patient-involvement. We hope that this will lead to high quality research that can impact patient management in a meaningful way.

Venesection for idiopathic and secondary erythrocytosis

The evidence for meaningful benefit of venesection in patients with idiopathic and secondary erythrocytosis is extremely scanty. We understand that practice is highly heterogeneous with some clinicians advocating venesection to maintain haematocrit <0.55 for example, and others not venesectioning at all. We aim to 1) understand the variations in practice and the reasons for this, 2) gather retrospective, observational data on the outcomes of patients who are venesected vs not venesected, and 3) work towards a randomised controlled trial.

Audit of management of neonatal ITP

Neonatal ITP is a rare disease and clinical practice is likely heterogeneous. The aim of this project is to prospectively audit care in such cases focusing on protocols, neonatal management and maternal counselling.

FUNDING AWARDS

We were able to fund two registrars (Giulia Simini and Allie Delaney) to attend the ISTH Conference in London in 2022 who would have otherwise not been able to attend.

OPEN ACCESS FEES

We paid for two journal publications that would otherwise have been behind journal paywalls to be open access and thus increase their impact.

CONFERENCE

In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 6/2/23 at The Catalyst in Newcastle. This comprised updates and results on current HaemSTAR projects, keynote talks from experts in the field of sickle cell disease, bleeding and ITP as well as a discussion session about future projects and future direction of HaemSTAR. Very positive feedback. Good industry engagement. Done with free registration and zero cost through industry funding.

Additional details of objectives and activities (Optional information)

You **may choose** to include further statements, where relevant, about:

- policy on grantmaking;
- policy programme related investment;
- contribution made by volunteers.

Section D

Achievements and performance

Section D

Achievements and performance

Summary of the main achievements of the charity during the year

Funding

Successfully secured grant funding from AstraZeneca for RAPIDO Project £88,000 to be received in 5 installments of £17,600 on completion of various project milestones.

- Fully executed research agreement
- Commencement of 1st data collection window
- Completion of 1st data collection window
- Completion of 2nd data collection window
- Completion of final study report / draft publication

Conference abstracts:

Crossette-Thambiah C, Rajakaruna I, Odho Z, Doyle A, Breen K, Laffan M, Arachchillage DJ. Anticoagulation Practice, Recurrent Thrombosis, and Major Bleeding in Antiphospholipid Syndrome- a Multicentre Observational Study in the United Kingdom. *ASH Annual Congress* (2022) 140 (Supplement 1): 347–349.

Cain L, HaemSTAR collaborators, Morton S. The ‘two sample rule’ in emergency departments: A UK-wide survey of junior doctors/physician associates. *BSH Annual Scientific Meeting* (2023). <https://doi.org/10.1111/bjh.18718>

Buka RJ, Pettitt M, Sutton D, Doyle A³, Lowe GC, Perry R, Magill L, Alikhan R, Nicolson PLR, HaemSTAR Collaborators. RAPIDO: Results from a UK-wide audit of reversal agents for direct oral anticoagulant associated bleeding. <https://doi.org/10.1111/bjh.18720>

Publications:

- Wilson L, Doyle AJ, Millen EA, Bull T, Biss T, Hart D, Lowe GC, Toh CH, Buka RJ, Nicolson PLR. HaemSTAR – growing experience from a national, trainee-led research network. *Hemasphere*. 2022;6(9):e766 <https://doi.org/10.1097/HS9.0000000000000766>
- Arachchillage D; Rajakaruna I, Pericleous C, Nicolson PLR, Makris M, Laffan M & CA-COVID-19 Study Group) Autoimmune disease and COVID-19- a multicentre observational study in the United Kingdom. *Rheumatology*. 2022;61(12):4643-4655 <https://doi.org/10.1093/rheumatology/keac209>
- Shaw RJ, Doyle AJ, Millen EA, Stowe J, Tessier E Andrews N, Miller N & HaemSTAR Collaborators. Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria. *Vaccine*. 2023; 41(36):5330-5337 <https://doi.org/10.1016/j.vaccine.2023.06.006>

Section E

Financial review

Brief statement of the charity's policy on reserves

We do not have a reserve policy.

Cash in bank at 31/3/23 was £81,007.44 in unrestricted funds. Our committed spending for 2023-24 comprises website hosting fees of approximately £<300 as well as a significant amount of money (but <£80k) for paying for project management support for the RAPIDO project. This is fully funded through the successful AstraZeneca Grant. It is unlikely that this represents any significant financial risk. For 2023-24 we hope to be able to use our funds to further support registrars attending conferences and other academic meetings, to make research publications open access, to run our own conference / meeting and to support research studies. We aim to apply for further funding to be able to fund significantly more people to attend scientific meetings. We intend to start a series of educational events including webinars and podcasts. These are dependent on funding / support from partner organisations. They will not go ahead if we haven't secured sufficient funding. All the projects currently active are fully funded. To develop the more aspirational elements of the projects in set up we will need to gain significant further grant funding.

Details of any funds materially in deficit

None.

Further financial review details (Optional information)

You **may choose** to include additional information, where relevant about:

- the charity's principal sources of funds (including any fundraising);
- how expenditure has supported the key objectives of the charity;
- investment policy and objectives including any ethical investment policy adopted.

Section F Other optional information

--

Section G Declaration

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity’s trustees

Signature(s)		
Full name(s)	Dr Phillip LR Nicolson	
Position (eg Secretary, Chair, etc)	President	
Date	24/1/24	